Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00642694 · ClinicalTrials.gov registry record · Phase 3
Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon
A Phase 3 study, sponsored by University of Texas Southwestern Medical Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 29
- Enrollment target
NCT00642694: Clinical Trial Phase 3 study, sponsored by University of Texas Southwestern Medical Center.
NCT00642694 is a Phase 3 study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 29 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00642694, a Phase 3 study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 29 participants
- Enrollment target
Study Summary
Hypothesis I: Patients in the SSRI + ramelteon treatment group will achieve remission (defined as an IDS-C30 score of 11 or less) more quickly than those in the SSRI + placebo group.
Primary Outcome
Remission as defined by a score of \<12 on the Inventory of Depressive Symptomatology, Clinician-Rated version (IDS-C30) at Week 12; minimum possible score = 0, maximum possible score = 84; higher scores indicate worse symptom severity
Interventions
- OTHER Placebo
- DRUG Escitalopram
- DRUG Ramelteon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
Why NCT00642694 stopped before completion
NCT00642694 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00642694 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00642694 about?
NCT00642694 is a clinical study titled "Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon". Hypothesis I: Patients in the SSRI + ramelteon treatment group will achieve remission (defined as an IDS-C30 score of 11 or less) more quickly than those in the SSRI + placebo group.
What is the current status of trial NCT00642694?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 29 participants. The study started on 2007-05. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00642694?
The interventions under investigation include: Placebo (OTHER), Escitalopram (DRUG), Ramelteon (DRUG).
Who is sponsoring clinical trial NCT00642694?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00642694's enrollment target sits among peer trials
29 1933rd of 2000 higher than 66 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia